secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001104659-26-029992
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics Q4 loss $3.8M; Halneuron Phase 2b >50% enrolled, top-line Q3 2026
--------------------------------------------------------------------------------

- Net loss Q4 2025 $3.8M ($0.26/share) vs $8.2M ($6.29) in Q4 2024; full year loss $35.5M ($7.13).
- Cash $6.5M at Dec 31, 2025; Jan 2026 financing raised $11.4M net to fund through Phase 2b readout.
- Halneuron CINP Phase 2b >50% enrolled; interim analysis showed separation from placebo; top-line expected Q3 2026.
- R&D expenses FY 2025 $21.8M (up from $3.5M) due to $12.0M SP16 license fee and clinical trial costs.
- G&A expenses fell to $6.1M from $8.7M due to lower nonrecurring transaction costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926029992/0001104659-26-029992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926029992/dwtx-20260318x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-029992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer